Search clinical trials for: HFA MDI

Total 465 results

AstraZeneca
Parexel

Not yet recruiting

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)

Healthy

Germany
AstraZeneca

Recruiting

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
GlaxoSmithKline

Not yet recruiting

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma

Asthma

Argentina, United States, Canada, Panama, Greece, France, Poland, Italy, United Kingdom
AstraZeneca

Recruiting

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Heathy Participants

United States
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Canada, India, Bulgaria, Poland
AstraZeneca

Recruiting

Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Compared to HFA MDI Propellant in Healthy Participants

Mucociliary Clearance

United States
Intech Biopharm Ltd.

Recruiting

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma

Mild Asthma

Taiwan, India
Organon and Co

Completed

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (SPIRO)

Asthma
Organon and Co

Completed

Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)

Asthma
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
Boehringer Ingelheim

Completed

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
Boehringer Ingelheim

Completed

Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
AstraZeneca

Completed

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Asthma

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Parexel

Completed

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma

Asthma

United States
Organon and Co

Withdrawn

Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)

Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
Parexel

Completed

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Asthma

United States
Intech Biopharm Ltd.
Peking University People's Hospital; Beijing Friendship Hospital; The Second... and other collaborators

Completed

Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients

Asthma

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Exercise-induced Bronchospasm

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Albuterol HFA MDI in Pediatric Participants With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Asthma

United States, Canada, Czechia, Hungary, Poland, Russian Federation, South Africa, Thailand, Ukraine
Lupin, Inc.

Completed

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Mild Persistent Asthma

United States
AstraZeneca

Completed

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

Asthma

United States
Concentrx Pharmaceuticals, Inc.
PharPoint Research, Inc.; Kramer Consulting, LLC

Completed

Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

Asthma

United States
Concentrx Pharmaceuticals, Inc.
PharPoint Research, Inc.; Kramer Consulting, LLC

Completed

Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma

Asthma

United States
Amphastar Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy and Safety of E004 in Children With Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

Asthma | Shortness of Breath | Wheezing | Bronchospasm

United States
GlaxoSmithKline

Completed

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Asthma

Japan
GlaxoSmithKline

Completed

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Pulmonary Disease, Chronic Obstructive

United States
Sunovion

Terminated

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

Asthma

United States
Amphastar Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

Asthma

United States
Intech Biopharm Ltd.

Completed

Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers

Asthma

Taiwan
Intech Biopharm Ltd.

Completed

Efficacy Study of SYN006 HFA MDI in Asthma Patients

Asthma

Taiwan
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Bronchial Asthma

Japan
Boehringer Ingelheim

Completed

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)

Asthma
Boehringer Ingelheim

Terminated

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Asthma

United States, Brazil, China, Colombia, Germany, India, Japan, Mexico, Peru, Poland, Romania
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Asthma

United States, Brazil, China, Guatemala, India, Japan, Latvia, Mexico, Peru, Poland, Russian Federation
Boehringer Ingelheim

Completed

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

Asthma

United States
Boehringer Ingelheim

Completed

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Asthma

United States
GlaxoSmithKline

Completed

Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).

Asthma

Australia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Asthma | Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States

3

Subscribe